These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL.
    Author: Reinis M.
    Journal: Curr Opin Mol Ther; 2004 Apr; 6(2):206-11. PubMed ID: 15195933.
    Abstract:
    CSL, licensee of UniQuest's HPV technology, and Aventis Pasteur MSD (a joint venture between Merck & Co and Aventis) are jointly developing a vaccine for the potential prophylaxis of genital warts and cervical cancer caused by human papilloma virus infection. Enrollment for a phase III trial has been completed.
    [Abstract] [Full Text] [Related] [New Search]